Accuray Inc.: Prostate Cancer Study Results Published on Patients Treated With CyberKnife Radiosurgery Erectile Function Preserved in More Than 80 Percent of Patients
SUNNYVALE, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Accuray Incorporated , a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery. The study demonstrated that erectile function was preserved in 81 percent of patients at a median follow-up of two years. Published rates of erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, range from 50-70 percent.
This study of 112 patients, led by a team of two radiation oncologists, a urologist and a physicist, achieved 97 percent sustained PSA response at two years, with urinary and rectal side effect profiles comparable to conventional radiation therapy. CyberKnife prostate radiosurgery is a non-invasive, outpatient treatment that is typically completed in a single week, making it more convenient for patients than six to eight weeks of conventional radiation therapy or an invasive surgical treatment that requires patients to have general anesthesia and an overnight hospital stay.
Click here to see how prostate cancer is treated with the CyberKnife System.
"The CyberKnife's ability to track and correct for movement of the prostate allowed us to focus our radiation dose on the prostate and spare surrounding tissues, like the nerves, resulting in erectile function preservation in a majority of our patients," said David M. Spellberg, M.D. "These data are encouraging for the millions of men diagnosed with prostate cancer looking for a non-invasive therapy that will preserve their quality of life."
"I was looking for a treatment that offered the best chance for a complete cure, but at the same time, it was extremely important to me to avoid the complications - impotence, incontinence and bowel problems - that commonly result from prostate cancer treatment," said study participant and retired Orthopedic Surgeon Scott Silver, M.D. "I am pleased to report three and a half years post-treatment, I remain cancer-free with my quality of life 100 percent intact."
The complete manuscript appears today in the Technology in Cancer Research & Treatment, and can also be found online at http://www.tcrt.org/index.cfm?d=3036&c=4295&p=17748&do=detail
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. Treatments are completed in five or fewer outpatient visits and patients can typically return to normal activities immediately following treatment.
About Accuray
Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 176 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, as to system utilization, clinical studies, patient and clinician acceptance, and performance of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: clinical results, commercialization of products; market acceptance of products; competing products; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2009 fiscal year and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Euan Thomson, Ph.D.
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869
Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Omar Dawood, M.D., MPH
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=85068
SOURCE Accuray Incorporated
CONTACT: Stephanie Tomei, Senior Manager, Marketing Communications of
Accuray Incorporated, +1-408-789-4234, stomei@accuray.com; or Brianne
Donahue of Schwartz Communications, +1-415-817-2545,
bdonahue@schwartz-pr.com, for Accuray Incorporated
Web site: http://www.accuray.com/